Rob Stein
Rob Stein is a correspondent and senior editor on NPR's science desk.
An award-winning science journalist with more than 30 years of experience, Stein mostly covers health and medicine. He tends to focus on stories that illustrate the intersection of science, health, politics, social trends, ethics, and federal science policy. He tracks genetics, stem cells, cancer research, women's health issues, and other science, medical, and health policy news.
Before NPR, Stein worked at The Washington Post for 16 years, first as the newspaper's science editor and then as a national health reporter. Earlier in his career, Stein spent about four years as an editor at NPR's science desk. Before that, he was a science reporter for United Press International (UPI) in Boston and the science editor of the international wire service in Washington.
Stein's work has been honored by many organizations, including the National Academy of Sciences, the American Association for the Advancement of Science, the American Association for Cancer Research, and the Association of Health Care Journalists. He was twice part of NPR teams that won Peabody Awards.
Stein frequently represents NPR, speaking at universities, international meetings and other venues, including the University of Cambridge in Britain, the World Conference of Science Journalists in South Korea, and the Aspen Institute in Washington, DC.
Stein is a graduate of the University of Massachusetts, Amherst. He completed a journalism fellowship at the Harvard School of Public Health, a program in science and religion at the University of Cambridge, and a summer science writer's workshop at the Marine Biological Laboratory in Woods Hole, Mass.
-
FDA advisers recommended the agency authorize new COVID-19 vaccines targeted at omicron to protect people against what could be another winter surge.
-
The Food and Drug Administration is meeting on Tuesday to make an extremely difficult but important decision: Should vaccines be updated to target the omicron variant?
-
The Food and Drug Administration is meeting on Tuesday to make an extremely difficult but important decision: Should vaccines be updated to target the omicron variant?
-
Centers for Disease Control and Prevention Director Rochelle Walensky has cleared the way for the roll out of vaccines for children five years and under as early as this coming week.
-
Some scientists estimate that cases of long COVID from omicron will still rise, however, because of high transmissibility and the misconception that people don't have to worry about catching it. -
Food and Drug Administration advisers are opening a two-day meeting to review Moderna and Pfizer-BioNTech's COVID-19 vaccines for children, including the first vaccines for kids younger than age 5.
-
Food and Drug Administration has released Moderna's data supporting the company's claim that its pediatric vaccines appear to be safe and effective, including for children as young as six months old.
-
Moderna says a new version of the company's COVID-19 vaccine appears to be highly effective against the omicron variant.
-
Moderna saysa new version of its COVID-19 vaccine appears to provide strong protection against the omicron variant as well as the original viral strain.
-
The "bivalent" vaccine — meaning it targets two different antigens — is Moderna's leading candidate for an effective booster this fall. If the data pan out, it could lead to a yearly booster.
